Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

BACKGROUND: Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueland, Thor, Åkerblom, Axel, Ghukasyan, Tatevik, Michelsen, Annika E., Aukrust, Pål, Becker, Richard C., Bertilsson, Maria, Himmelmann, Anders, James, Stefan K., Siegbahn, Agneta, Storey, Robert F., Kontny, Frederic, Wallentin, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850148/
https://www.ncbi.nlm.nih.gov/pubmed/29330256
http://dx.doi.org/10.1161/JAHA.117.007009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850148/
https://www.ncbi.nlm.nih.gov/pubmed/29330256
http://dx.doi.org/10.1161/JAHA.117.007009

Ejemplares similares